COVID-19相关肺栓塞后慢性血栓栓塞性肺动脉高压与血栓溶解
本研究为多中心横断面研究,旨在明确COVID-19相关肺栓塞幸存者中慢性血栓栓塞性肺动脉高压(CTEPH)及复发性静脉血栓栓塞症的患病率,并评估血栓溶解情况。结果提示,COVID-19相关肺栓塞后CTEPH并非比非COVID-19肺栓塞更常见,血栓溶解似乎也无差异。
要点
- COVID-19相关肺栓塞后CTEPH患病率不高于非COVID-19肺栓塞。
- COVID-19相关肺栓塞后血栓溶解与非COVID-19肺栓塞相似。
- CTEPH不应被视为COVID-19相关肺栓塞特有的长期并发症。
核心结论
- COVID-19相关肺栓塞后CTEPH并不比非COVID-19肺栓塞更常见,血栓溶解也无明显差异。
研究设计与样本
- 多中心横断面研究,对象为COVID-19相关肺栓塞幸存者。
主要发现
- 研究旨在确定COVID-19相关肺栓塞幸存者中CTEPH和复发性VTE的患病率并评估血栓溶解。
- 结果提示CTEPH并非COVID-19相关肺栓塞后更常见的长期并发症。
- 血栓溶解情况与非COVID-19相关肺栓塞似乎无差异。
临床怎么用
- 对COVID-19相关肺栓塞幸存者,CTEPH的长期监测策略可参考非COVID-19肺栓塞人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The results of this study suggest that CTEPH is not a more common long-term complication after COVID-19-associated PE than after PE in non-COVID-19 patients, and thrombus resolution did not seem to be different from non-COVID-19-associated PE https://bit.ly/3IjvWL3 The incidence of chronic thromboembolic pulmonary hypertension (CTEPH) in coronavirus disease 2019 (COVID-19) survivors who were diagnosed with acute pulmonary embolism (PE) is currently unknown. Considering the high PE incidence reported in COVID-19 and its potentially unique pathophysiology, it may be hypothesised that thrombus resolution occurs to a lesser extent after COVID-19-associated PE, and that the prevalence of CTEPH is higher compared to non-COVID-19-associated PE populations. CTEPH could therefore be a treatable cause of long COVID, which captures a broad range of post-acute COVID-19 sequelae, in those with PE during acute COVID-19 [1]. In this multicentre cross-sectional study, we aimed to establish the prevalence of CTEPH and recurrent venous thromboembolism (VTE), and evaluate thrombus resolution in COVID-19-associated PE survivors.
引用
- de Jong, Visser, Bemelmans, et al. Chronic thromboembolic pulmonary hypertension and clot resolution after COVID-19-associated pulmonary embolism. Eur Respir J. 2023. PMID: 37080574. doi:10.1183/13993003.00171-2023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。